Healthlead Public (HL) Fundamentals 2026 — P/E 20.8x, Revenue Analysis | SniperIQ
Healthlead Public (HL) is a TH-listed Healthcare company in Medical - Distribution with a market capitalization of ฿1.5B, trading at ฿5.85 on the SET. This SniperIQ fundamentals page covers Healthlead Public's valuation (P/E 20.8x, P/B 1.6x), profitability (net margin 3.4%), revenue (฿2.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Healthlead Public's market cap?
Healthlead Public (HL) has a market capitalization of approximately ฿1.5B, trading at ฿5.85 on the SET. Market cap moves with the live share price.
What is Healthlead Public's P/E ratio?
Healthlead Public's trailing twelve-month P/E ratio is 20.8x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Healthlead Public?
Healthlead Public runs a net profit margin of 3.4%, a gross margin of 24.5%, and an operating margin of 3.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Healthlead Public generate?
Healthlead Public reported revenue of ฿2.2B for fiscal year 2025, with net income of ฿78M and earnings per share (EPS) of 0.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Healthlead Public pay a dividend?
Healthlead Public offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Healthlead Public financially healthy?
Healthlead Public carries a debt-to-equity ratio of 0.34x and a current ratio of 3.03x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Healthlead Public a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Healthlead Public (HL) the key facts are: market cap ฿1.5B, P/E 20.8x, revenue ฿2.2B, 52-week range 5.4-8.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Healthlead Public's full fundamentals live
Get Healthlead Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.